Zacks Research Forecasts OPKO Health FY2028 Earnings

OPKO Health, Inc. (NASDAQ:OPK) – Equities researchers at Zacks Research issued their FY2028 earnings per share (EPS) estimates for OPKO Health in a research report issued to clients and investors on Thursday, March 19th. Zacks Research analyst Team forecasts that the biotechnology company will post earnings per share of ($0.16) for the year. The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share.

A number of other brokerages also recently weighed in on OPK. Wall Street Zen downgraded OPKO Health from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, January 22nd. Barrington Research dropped their price objective on shares of OPKO Health from $2.25 to $1.50 and set an “outperform” rating on the stock in a research note on Monday, March 2nd. Finally, JPMorgan Chase & Co. started coverage on shares of OPKO Health in a research report on Thursday, November 20th. They issued a “neutral” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, OPKO Health has an average rating of “Hold” and an average target price of $2.03.

OPKO Health Stock Performance

Shares of NASDAQ OPK opened at $1.17 on Friday. The company has a current ratio of 3.97, a quick ratio of 3.52 and a debt-to-equity ratio of 0.26. OPKO Health has a one year low of $1.11 and a one year high of $1.86. The business has a 50-day moving average price of $1.24 and a two-hundred day moving average price of $1.34. The firm has a market capitalization of $888.11 million, a PE ratio of -3.90 and a beta of 1.50.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03. The business had revenue of $148.50 million for the quarter, compared to the consensus estimate of $139.76 million. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.OPKO Health’s revenue for the quarter was down 19.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.01 earnings per share.

Institutional Trading of OPKO Health

A number of institutional investors and hedge funds have recently made changes to their positions in OPK. Caprock Group LLC acquired a new position in shares of OPKO Health during the 3rd quarter valued at about $26,000. Swiss Life Asset Management Ltd bought a new position in shares of OPKO Health in the 3rd quarter valued at approximately $30,000. Zacks Investment Management acquired a new stake in OPKO Health in the 4th quarter worth approximately $27,000. Savant Capital LLC bought a new stake in OPKO Health during the third quarter worth approximately $33,000. Finally, StoneX Group Inc. bought a new stake in OPKO Health during the fourth quarter worth approximately $27,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.